Gene editing cuts “bad” cholesterol by as much as 55% in first human trial, a potential one‑time treatment for high cholesterol
A New England Journal of Medicine study reports the first successful in‑body CRISPR base editing trial that reduced LDL cholesterol up to 55% after a single VERVE‑101 infusion, offering potential for a one‑time treatment for high cholesterol.
Key takeaways
- One infusion: A single intravenous dose of VERVE‑101 delivered via lipid nanoparticles produced up to ~55% LDL reduction at the highest dose by day 28.
- Early safety: Side effects were mostly mild; one serious heart rhythm event occurred but did not require hospitalization in this small cohort.
- Durability signal: LDL lowering persisted for months, suggesting potential for durable or permanent benefit from in‑body base editing.
- Limitations: This was a Phase 1b pilot with 10 adults with heterozygous familial hypercholesterolemia — larger, longer trials are needed to assess rare risks and broader effectiveness.
Key information
- The trial, published in the New England Journal of Medicine (original study), was led by Verve Therapeutics and tested an in‑body CRISPR base editing therapy called VERVE‑101.
- Ten adults with heterozygous familial hypercholesterolemia (a genetic cause of very high LDL cholesterol) participated while continuing standard cholesterol medicines.
- Delivery used lipid nanoparticles (similar technology to some COVID‑19 vaccines) to carry the base editing machinery to the liver via one intravenous infusion.
- No clear off‑target edits were detected in this small sample, but larger studies are required to detect rare unintended changes.
How the study worked
Researchers targeted the PCSK9 gene in liver cells — a key regulator of LDL receptor levels. Instead of cutting both DNA strands, they used CRISPR base editing to swap a single DNA letter (an A to a G) to disrupt PCSK9 function. The editing payload was encapsulated in lipid nanoparticles to reach hepatocytes after systemic infusion.
Results and early signals of effectiveness
At the highest dose cohort, participants experienced roughly a 55% reduction in LDL cholesterol by day 28. Preliminary follow‑up indicated that the LDL lowering persisted for months, suggesting the edits in liver cells produced a durable effect. If sustained, this magnitude of LDL reduction would be clinically meaningful for reducing heart attacks and strokes.
Safety, limitations and unanswered questions
- Adverse events: Most side effects were mild (flu‑like symptoms, transient liver enzyme elevations). One participant had a serious heart rhythm abnormality that did not require hospitalization and is under continued monitoring.
- Off‑target risk: No clear off‑target edits were seen in this small group, but detecting rare unintended genomic changes will require larger cohorts and long follow up.
- Generalisability: Participants had a specific genetic form of very high LDL; effectiveness in people without that condition or as a general preventive measure remains unknown.
- Long‑term unknowns: Immune responses, unforeseen genomic effects, durability over years and safety in diverse populations must be established through further trials.
Voices from the field
“The goal is a one‑time therapy that could dramatically reduce heart disease risk,” said Verve Therapeutics co‑founder and CEO Dr. Sekar (Sek) Kathiresan, describing the company’s ambition.
Geneticists and cardiologists called the study a milestone for in‑body gene editing. Dr. Daniel MacArthur described the work as an important step toward safely “rewriting” the human genome for common diseases. At the same time, many experts urge caution and emphasize the need for long‑term monitoring and broader trials.
Why PCSK9 matters
PCSK9 influences the number of LDL receptors on liver cells: higher PCSK9 activity lowers receptor numbers and raises circulating LDL. Existing PCSK9 inhibitors (injection drugs) reduce LDL and heart events; editing the PCSK9 gene aims to replicate or exceed those benefits with a single, durable intervention.
What CRISPR base editing is
CRISPR base editing is a precision approach that makes a single‑letter DNA change without generating a double‑strand break. By converting one nucleotide to another, base editors can disrupt a gene more subtly than traditional cut‑and‑repair techniques, which may lower some safety risks. In this trial, base editing was performed in vivo (inside patients) in liver cells.
Regulatory and development pathway
This Phase 1b trial represents an early, first‑in‑human step. If larger studies confirm safety and durable benefit, the therapy would need to progress through additional clinical phases and regulatory review before potential approval. Cost, access and equity questions will be central — one‑time advanced therapies can be expensive and raise complex policy decisions for health systems and patients.
Implications for San Diego
Economic impact
San Diego’s growing biotech sector could see renewed investor and research interest in gene editing and lipid nanoparticle delivery platforms. Expanded trial activity could bring jobs and clinical research infrastructure to local institutions.
Clinical care and patients
Local cardiologists and lipid specialists may face increased patient questions about gene editing as a potential one‑time alternative to statins or PCSK9 injections. For now, standard therapies remain the proven options.
Public health and prevention
Even if gene editing becomes available, population‑level prevention (smoking cessation, healthy diets, blood pressure control) will remain essential; editing addresses one biological pathway and does not replace lifestyle or community interventions.
Ethics, access and local debate
San Diego communities will need to weigh benefits against ethical concerns about permanent DNA changes, prioritize diverse trial recruitment, and plan for equitable access if such therapies are approved.
Research and training
Universities and hospitals in the region may expand training in genetic medicine, bioethics and clinical trial design, strengthening San Diego’s role in precision medicine while requiring public engagement and oversight.
Sources and further reading
- New England Journal of Medicine (original study)
- Verve Therapeutics (company information and press materials)
- Associated Press coverage
- Reuters coverage
- The New York Times coverage
- PubMed/National Library of Medicine
Reporting and verification
This article is based on the trial report published in the New England Journal of Medicine (original study) and contemporaneous coverage and statements from Verve Therapeutics (company information and press materials) and independent experts. The findings are preliminary from a small Phase 1b trial; long‑term safety and broader effectiveness must be confirmed in larger studies before clinical adoption.
